<DOC>
	<DOCNO>NCT01626248</DOCNO>
	<brief_summary>The purpose study research association receive Tysabri® ( natalizumab ) , interferon beta-1a , glatiramer acetate treatment MS may may impact certain white blood cell immunological marker . This information may useful identify risk factor develop progressive multifocal leukoencephalopathy ( PML ) . It appear risk increase total number natalizumab infusion . Patients yet start disease modify therapy one natalizumab need control see biomarkers change . Patients various stage natalizumab treatment well natalizumab naïve need allow analysis change potential marker time .</brief_summary>
	<brief_title>Analysis Lymphocyte Cell Surface Adhesion Marker Expression Natalizumab Population With Active Control</brief_title>
	<detailed_description>Patients various timepoints MS treatment begin certain MS treatment consent blood specimen collect allow immunological comparison . The decision treat disease modify therapy make independently observational study . Primary endpoint : To understand delineation lymphocyte cell adhesion marker regulation within treatment naïve patient population various stage treatment . Secondary endpoint : To understand correlation natalizumab pharmacodynamics , pharmacokinetics lymphocyte cell adhesion marker regulation . The result various biomarkers immunological testing ( include CD62L , LFA-1 , sCD62L , sLFA-1 , sVCAM , VLA-4 saturation , IgG4 , CBC absolute differential ) compare amongst group consent . The treatment naive group compare longitudinally .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>1 . Ability understand purpose risk study provide sign date informed consent authorization use protect health information ( PHI ) accordance national local subject privacy regulation . 2 . Aged 18 80 year old , inclusive , time informed consent . 3 . Patients relapse form Multiple Sclerosis determine treat backup neurologist per chart review . 4 . If get natalizumab schedule commence natalizumab infusion patient must enrol TOUCH Prescribing Program expect discontinue Tysabri® therapy prior completion requirement study must currently prescribe use interferon beta 1a glatiramer acetate injection 18 month ; , naïve natalizumab , interferon beta 1a glatiramer acetate begin treatment consent . 5 . Patients screen Group A must completely naïve natalizumab , patient begin interferon beta1a glatiramer acetate must also naïve natalizumab . 6 . Patients screen natalizumab naïve must least 30 day clear disease modify therapy . 7 . Patients must free know systemic bacterial viral infection . 8 . No fever 99.5 degree Fahrenheit last two week Baseline prior schedule specimen collection . 9 . No herpes zoster outbreaks within last 30 day . 10 . No methylprednisolone sodium succinate infusion ( solumedrol ) corticosteroid use within last 30 day . 11 . Must weigh 44 190 kg , inclusive . 1 . Patient unwilling unable , opinion investigator , comply study instruction . 2 . Patients experience MS relapse exacerbation result methylprednisolone sodium succinate infusion 30 day prior Baseline 3 . Patients active , unknown infection etiology patient treat known infection would allow discretion Investigator , present sign infection diagnose exclude . 4 . Fever 99.6 high within last two week prior schedule specimen collection ( Baseline , 1 month , 3 month , 12 month 18 month ) . 5 . If patient miss dos DMT per inclusion criterion . 6 . No prior immunosuppressant use ( e.g. , mitoxantrone , azathioprine , methotrexate , cyclophosphamide , mycophenolate mofetil ) . 7 . Specimen collection must occur Monday Thursday .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Immunological</keyword>
	<keyword>biomarkers</keyword>
	<keyword>observational</keyword>
	<keyword>RRMS</keyword>
	<keyword>Relapsing</keyword>
	<keyword>Remitting Multiple Sclerosis</keyword>
</DOC>